PharmaNet hires vp for clinical operations

Catherine Derasp will oversee Phase I clinics

Catherine Derasp has joined PharmaNet Development Group, a US provider of clinical development services to the pharmaceutical and biotechnology industry, as vice president, clinical operations of the company's Phase I clinics.

Derasp will oversee the management of the company's 350-bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, she will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

You may also like

Manufacturing
Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?

Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?

Many facilities continue to rely on oil-lubricated vacuum pumps that were installed years ago. The question is no longer whether these pumps work. The question is whether they remain the most efficient solution for today's operational, environmental and productivity requirements
Manufacturing
Why CAPA keeps failing and what strong organisations do differently

Why CAPA keeps failing and what strong organisations do differently

This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
Manufacturing
Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Cloud-based environmental monitoring helps life science organisations establish professional-quality monitoring from day one and scale as requirements evolve
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
Manufacturing
ESTEVE CDMO invests $80m in new China API manufacturing site

ESTEVE CDMO invests $80m in new China API manufacturing site

The Shaoxing facility will provide 250 m³ of reaction volume, with potential capacity exceeding 400 m³, as the CDMO expands its global small-molecule API manufacturing network
Manufacturing
Ardena invests in tablet compaction technology to accelerate OSD drug development

Ardena invests in tablet compaction technology to accelerate OSD drug development

The CDMO has installed a KORSCH STYL’ONE Evo compaction simulator at its Ghent, Belgium, headquarters to reduce material use and support faster oral solid dose scale-up
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
Subscribe now